Evaluation of the effect of living donor liver transplantation on the treatment of severe hepatitis.
- Author:
Guo LI
1
;
Tian-Fu WEN
;
Lü-Nan YAN
;
Zhe-Yu CHEN
;
Yong ZENG
;
Bo LI
;
Ji-Chun ZHAO
;
Wen-Tao WANG
;
Jia-Yin YANG
;
Ming-Qing XU
;
Yu-Kui MA
;
Hong WU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Follow-Up Studies; Hepatitis B; physiopathology; surgery; Humans; Immunoglobulins; therapeutic use; Immunosuppressive Agents; therapeutic use; Kidney Function Tests; Lamivudine; therapeutic use; Liver Cirrhosis; physiopathology; surgery; Liver Function Tests; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Complications; therapy; Postoperative Period; Treatment Outcome; Young Adult
- From: Chinese Journal of Hepatology 2009;17(3):184-187
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of living donor liver transplantation on the treatment of severe hepatitis.
METHODS18 patients with severe hepatitis received liver transplantation (transplanted severe hepatitis group), 28 patients with sever hepatitis received non surgical treatment (non-transplanted severe hepatitis group), and 30 patients with end stage liver cirrhosis (without cancer) received liver transplantation (transplanted cirrhosis group). The vital sign, blood coagulation, and renal function were monitored during operation. After liver transplantation, patients received immunosuppressive therapy (including tacrolimus or cyclosporine A, mycophenolate, mofetil and corticosteroids), intensive care, antiviral therapy (including lamivudine and HBIg) and other treatments (including restoration of liver function and prevention of blood coagulation). Pre-operation data, operation procedure, liver function, renal function and the operation complications of three groups were compared, and survival rate at 1, 6 and 12 months after operation was followed.
RESULTSThere was no significant difference in the operation time, warm ischemia time, hypothermic ischemia time and Graft-to-recipient weight ratio between the two transplantation groups. The blood loss volume and blood transfusion volume in the transplanted severe hepatitis group were higher than that those in the cirrhosis transplantation group (t = 0.001, 0.004). The levels of TBil, ALT and AST at day 7 after operation were (100.5 +/- 96.4)mumol/L, (215.3 +/- 195.7) U/L , (209.8 +/- 188.6) U/L in the transplanted severe hepatitis group, and (53.3 +/- 31.9)mumol/L, (56.3 +/- 22.1) U/L, (51.3 +/- 13.5) U/L in the transplanted cirrhosis group (t = 0.017, 0.021, 0.004). However, there was no significant difference in the levels of Alb and Cr between these two groups (P > 0.05). Survival rate was 88.89%, 83.33% 83.33% in the transplanted severe hepatitis group, and 96.67%, 93.33% 93.33% in the transplanted cirrhosis group at 1, 6 and 12 months after transplantation.
CONCLUSIONLiving donor liver transplantation is one of effect ways for the treatment of severe hepatitis.
